Vebreltinib

Vebreltinib
Clinical data
Other names	Bozitinib; APL-101; PBL-1001
Routes of; administration	Oral
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name 6-(1-Cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine;
CAS Number	1440964-89-5;
PubChem CID	72202701;
DrugBank	DB16823;
ChemSpider	72388443;
UNII	2WZP8A9VFN;
ChEMBL	ChEMBL4650443;
Chemical and physical data
Formula	C20H15F3N8
Molar mass	424.391 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F;
	InChI InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3; Key:QHXLXUIZUCJRKV-UHFFFAOYSA-N;

Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer.^[1]^[2]

Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways.^[3]

In China, it is approved for the treatment of non-small-cell lung cancer (NSCLC) with MET exon 14 skipping mutations.^[4]

References

^ Hong L, Zhang J, Heymach JV, Le X (2021). "Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer". Therapeutic Advances in Medical Oncology. 13 1758835921992976. doi:10.1177/1758835921992976. PMC 7890719. PMID 33643443.
^ Han Y, Yu Y, Miao D, Zhou M, Zhao J, Shao Z, et al. (February 2024). "Targeting MET in NSCLC: An Ever-Expanding Territory". JTO Clinical and Research Reports. 5 (2) 100630. doi:10.1016/j.jtocrr.2023.100630. PMC 10867448. PMID 38361739.
^ "Vebreltinib". NCI Drug Dictionary. U.S. National Institutes of Health.
^ "Vebreltinib Receives Approval in China For MET Exon 14+ NSCLC". onclive.com. November 16, 2023.